Validation of lexicographic optimisation-based planning for locally advanced cervical cancer
OC-0127
Abstract
Validation of lexicographic optimisation-based planning for locally advanced cervical cancer
Authors: Sara Trivellato1, Paolo Caricato1,2, Roberto Pellegrini3, Gianluca Montanari1, Valeria Faccenda1,2, Sofia Meregalli4, Elisa Bonetto4, Stefano Arcangeli4,5, Elena De Ponti1,5
1ASST Monza, Medical Physics Department, Monza, Italy; 2University of Milan, Department of Physics, Milan, Italy; 3Elekta AB, Global Clinical Science, Stockholm, Sweden; 4ASST Monza, Department of Radiation Oncology, Monza, Italy; 5University of Milan Bicocca, School of Medicine and Surgery, Milan, Italy
Show Affiliations
Hide Affiliations
Purpose or Objective
Recent advances in automated treatment planning demonstrated improved
plan quality and best practice reducing routine planning workload. In this
study, a not yet commercially available fully-automated lexicographic
optimisation (LO) planning, called mCycle (Elekta AB, Stockholm), has been
validated for locally advanced cervical cancer.
Material and Methods
Twenty cervical cancer treatment plans (50 Gy in 25 fx) delivered between
November 2019 and July 2021 have been retrospectively selected and re-planned
by mCycle (Monaco 5.59.13). Constraints and objectives were sequentially
optimized by multi-criterial optimization (MCO) according to an a-priori
assigned priority list, a so-called Wish List (WL). Four patient sets have been
used to achieve a robust WL. Main criteria for planning approval were a target
coverage V95% > 97% (acceptable > 95%), target D1% <
105%, a bowel volume receiving more than 45 Gy less than 195 cm3 (V45
Gy < 195 cm3), rectum and bladder spared as much as
possible. Manual plan (MP) and mCycle plans (mCP) were compared in terms of
dose-volume constraints and plan complexity, i.e. MUs and modulation degree (MD),
performing the Wilcoxon Mann Whitney test to assess statistical significance (α=0.05).
Plan deliverability was verified by treatment QA.
Results
The re-planning of 20 plans took 3 working days. Plan comparison showed
an increased target dose coverage passing from a V95% of (97.1 ± 1.2)%
for MP to (98.1 ± 2.5)% for mCP (p = 0.002). The
median bowel V45Gy, rectum and bladder mean doses were 183.2 cm3,
39.4 Gy, and 40.7 Gy for MP and 189.7 cm3, 38.0 Gy, and 38.8 Gy for
mCP, respectively (p > 0.05). The average modulation degree was 3.1 ± 0.4
and 3.3 ± 0.3 for MP and for mCP, respectively (p > 0.05). The average MUs were
increased, registering 733.5 ± 84.0 and 797.3 ± 65.6 for MP and mCP,
respectively (p = 0.02) but registering a comparable gamma analysis (local
3%/3mm).
Conclusion
The
novel mCycle autoplanning produced high-quality clinically acceptable plans
significantly reducing the overall planning time: at our Institution, medical
physicists are typically given one day to optimize one cervical cancer treatment. While the OAR sparing was
comparable between MP and mCP, the target coverage was significantly increased.
Despite the higher MU number, the plan deliverability has been preserved. The
validation showed the mCycle capability to generate high-quality deliverable
plans according to institutional-specific planning protocols.